Francisco Gil-López

Francisco Gil-López

Auto-generated profile, based on publicly available information

Francisco Gil-López

Department of Neurology, Grupo Quirónsalud, Hospital Universitari Sagrat Cor, Universitat de Barcelona, Barcelona, Spain

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 July 2018 in Epilepsia
Verified
Journal Article
Closed access
PDF file
VVVicente Villanueva
Vicente Villanueva
JMJavier Montoya
Javier Montoya
ACAscension Castillo
Ascension Castillo
JMJosé Á. Mauri‐Llerda
José Á. Mauri‐Llerda
PGPau Giner
Pau Giner
JSJavier Salas‐Puig
Javier Salas‐Puig

3 December 2014 in Cerebrovascular Diseases
Verified
Journal Article
Closed access
PDF file
XUXabier Urra
Xabier Urra
ARAránzazu Román-San-Miguel
Aránzazu Román-San-Miguel
FGFrancisco Gil
Francisco Gil
MMMònica Millán
Mònica Millán
DCDavid Cánovas
David Cánovas
R(Reperfusion Consortium (Cat-SCR)
Reperfusion Consortium (Cat-SCR)
Background: A significant proportion of stroke patients presenting with mild symptoms does not have a successful recovery, especially when a large vessel is occluded. IV thrombolysis is safe and may benefit patients presenting with mild symptoms. In this study, we tested whether endovascular therapy (ET) is superior to medical therapy in these patients. Methods: Observational, prospectively collected, multicenter study of 78 consecutive patients admitted from 2009 to 2012 within 6 h of stroke, with NIHSS ≤5 at presentation or during initial diagnostic work-up and large vessel occlusion. Data for patients undergoing ET and/or IV thrombolysis were taken from the SONIIA registry of reperfusion therapies in Catalonia, or from our local stroke registry if no reperfusion therapy was delivered. We compared risk factors, clinical course, collateral circulation, revascularization rates, hemorrhagic complications, infarct volume, and the functional outcome at 3 months of patients treated with ET and those not receiving ET. Ordinal regression was used to assess the independent effect of ET on functional outcome. Results: Baseline characteristics were similar for ET (n = 34) and medically (n = 44) treated patients, except for older age in the latter. The occlusions were located in the terminal internal carotid artery (1%), M1 segment of the middle cerebral artery (33%), M2 segment (30%), posterior circulation (31%), and 5% of the patients had tandem lesions, with no significant differences between groups. Most patients in both treatment groups had good collateral flow. The rate of successful revascularization (91.2 vs. 63.4%; p = 0.006) and the risk of symptomatic intracranial hemorrhage (11.8 vs. 0%; p = 0.033) were higher in the ET group. The NIHSS scores were similar at hospital arrival, after initial neuroimaging, and at 24 h in both treatment groups and there were no significant differences in the infarct volume in a follow-up MRI. At 3 months, 35.9% of the patients had some disability. The functional outcome was similar in both treatment groups in univariate analysis and also in models adjusted for age and initial NIHSS or for variables associated to functional outcome on univariate comparison. Conversely, IV thrombolysis was associated with significantly greater chances of full recovery after adjusting for baseline differences (OR 3.70, p = 0.015). Conclusions: One third of stroke patients with mild symptoms and large vessel occlusions do not have a successful recovery. ET is effective to recanalize the occluded vessel but increases the risk of serious bleeding significantly without improving the functional outcome, and is therefore not justified routinely in these patients.

1 September 2020 in Brain Stimulation
Verified
Journal Article
Open access
FGFrancisco Gil-López
Francisco Gil-López
TBTeresa Boget
Teresa Boget
IMIsabel Manzanares
Isabel Manzanares
ADAntonio Donaire
Antonio Donaire
ECEstefanía Conde-Blanco
Estefanía Conde-Blanco
MCMar Carreño
Mar Carreño
External trigeminal nerve stimulation (ETNS) is an emergent, non-invasive neurostimulation therapy delivered bilaterally with adhesive skin electrodes. In previous studies, ETNS was associated to a decrease in seizure frequency in patients with focal drug-resistant epilepsy (DRE). To determine the long-term efficacy and tolerability of ETNS in patients with focal DRE. Moreover, to explore whether its efficacy depends on the epileptogenic zone (frontal or temporal), and its impact on mood, cognitive function, quality of life, and trigeminal nerve excitability. Forty consecutive patients with frontal or temporal DRE, unsuitable for surgery, were randomized to ETNS or usual medical treatment. Participants were evaluated at 3, 6 and 12 months for efficacy, side effects, mood scales, neuropsychological tests and trigeminal nerve excitability. Subjects had a median of 15 seizures per month and had tried a median of 12.5 antiepileptic drugs. At 12 months, percentage of responders was 50% in ETNS group and 0% in control group. Seizure frequency in ETNS group decreased by -43.5% from baseline. Temporal epilepsy subgroup responded better than frontal epilepsy subgroup (55.56% vs. 45.45%, respectively). Median stimulation intensity was 6.2 mA. ETNS improved quality of life, but not anxiety or depression. Long-term ETNS affected neither neuropsychological function, nor trigeminal nerve excitability. No relevant adverse events were observed. ETNS is an effective and well-tolerated therapy for focal DRE. Patients with temporal epilepsy showed a better response than those with frontal epilepsy. Future studies with larger populations may define its role compared to other neurostimulation techniques. This study provides Class II evidence that ETNS reduces seizure frequency in patients with focal DRE.

1 October 2020 in Neuromuscular Disorders
Verified
Journal Article
Closed access
LDLaura Diez-Porras
Laura Diez-Porras
EVEnric Vergés
Enric Vergés
FGFrancisco Gil
Francisco Gil
MVM José Vidal
M José Vidal
JMJoan Massons
Joan Massons
AAAdrià Arboix
Adrià Arboix

24 March 2018 in Acta Neurologica Scandinavica
Verified
Journal Article
Closed access
PDF file
FGF. J. Gil-López
F. J. Gil-López
JMJ. Montoya
J. Montoya
MFMercè Falip
Mercè Falip
JAJ. Aparicio
J. Aparicio
FLF. J. López-González
F. J. López-González
MCMar carreño
Mar carreño

21 December 2019 in Cerebral Cortex
Verified
Journal Article
Closed access
FGFrancisco Gil
Francisco Gil
NPNelly Padilla
Nelly Padilla
SSSara Soria-Pastor
Sara Soria-Pastor
XSXavier Setoain
Xavier Setoain
TBTeresa Boget
Teresa Boget
ADAntonio Donaire
Antonio Donaire
Focal epilepsy can be conceptualized as a network disorder, and the functional epileptic network can be described as a complex system of multiple brain areas that interact dynamically to generate epileptic activity. However, we still do not fully understand the functional architecture of epileptic networks. We studied a cohort of 21 patients with extratemporal focal epilepsy. We used independent component analysis of functional magnetic resonance imaging (fMRI) data. In order to identify the epilepsy-related components, we examined the general linear model-derived electroencephalography-fMRI (EEG–fMRI) time courses associated with interictal epileptic activity as intrinsic hemodynamic epileptic biomarkers. Independent component analysis revealed components related to the epileptic time courses in all 21 patients. Each epilepsy-related component described a network of spatially distributed brain areas that corresponded to the specific epileptic network in each patient. We also provided evidence for the interaction between the epileptic activity generated at the epileptic network and the physiological resting state networks. Our findings suggest that independent component analysis, guided by EEG–fMRI epileptic time courses, have the potential to define the functional architecture of the epileptic network in a noninvasive way. These data could be useful in planning invasive EEG electrode placement, guiding surgical resections, and more effective therapeutic interventions.